XKRX
006280
Market cap1.10bUSD
Oct 08, Last price
129,400.00KRW
1D
-0.84%
1Q
5.03%
Jan 2017
-17.58%
Name
Green Cross Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GC Biopharma Corp. is a pharmaceutical enterprise primarily involved in the production and distribution of various medical products. Its extensive portfolio encompasses specialized treatments for blood-related conditions, non-prescription remedies, general medications, and immunizations, among other therapeutic solutions. The company was established on November 1, 1969, and its principal corporate offices are situated in Yongin, South Korea.
Key people
Chairman · since 2014
Eun Cheol Huh
President, Chief Executive Officer, Director · since 2016
Jae Wuk Jung
Director · since 2024
Wung Shin
Director · since 2024
Chun Wu Lee
Non-Executive Independent Director · since 2020
Jin Hui Lee
Non-Executive Independent Director · since 2024
Gi Jun Park
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2024
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||